Tag: Johnson & Johnson

Johnson & Johnson: XARELTO Helps Protect Pediatric Patients from Blood Clots in Late-Breaking Phase 3 EINSTEIN-Jr Study

Originally posted on JNJ.com The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new results from the Phase 3 EINSTEIN-Jr study, showing pediatric patients (aged birth to 17 years) treated with XARELTO® (rivaroxaban) had a similar low risk of recurrent venous thromboembolism (VTE) – or blood clots – and similar…

johnson & johnson, major depressive disorder, mental health

Johnson & Johnson: New Evidence Highlights Need for Interventions to Improve Outcomes for Patients Wth Major Depressive Disorder and Suicide Ideation or Attempt

Data presented at the American Psychiatric Association 2019 Meeting suggest a low rate of psychiatric care received by adult patients with MDD before suicide ideation or attempt diagnosis Originally Published by Johnson & Johnson. Additional Data Show Patients Have a High Risk of Hospital Readmission or Subsequent Emergency Department Visit…

burnout, doctors, nurses, Johnson & Johnson, care

Johnson & Johnson: Caring for Care Providers: An Innovative Way to Help Address the Growing Crisis of Doctor and Nurse Burnout

Up to 70% of nurses and nearly 55% of physicians report symptoms of burnout, which costs workplaces millions of dollars a year due to lost productivity and employee turnover and absenteeism—and impacts patient quality of care. But the CareAdvantage program is poised to help. By Kristen Mascia Originally Published by…

Johnson & Johnson: From Aha! Moment to FDA Approval: The Fascinating Story Behind a New Treatment for Bladder Cancer

We retrace the 22-year journey it took to bring a potentially life-changing treatment for an aggressive form of the disease to patients who may benefit most. Originally Published by Johnson & Johnson. By Hallie Levine It’s the sixth most common cancer, yet treatment options formetastatic bladder cancer are limited. But now, there’s…